Seeking Alpha

Goldman's Terence Flynn says a study published in a medical journal suggests branded VEGF drugs...

Goldman's Terence Flynn says a study published in a medical journal suggests branded VEGF drugs such as Regeneron's (REGN +2.7%) Eylea "are superior to off-label Avastin." In the cited study, patients on Lucentis realized a 13 letter improvement in vision versus an 11 letter improvement for those on Avastin.
Comments (1)
  • lucagrs
    , contributor
    Comments (68) | Send Message
     
    Avastin's price is 1/10th of Lucentis' and Eyelea costs even more. Who would pay x10 for a 18% improvement of a non-life saving drug? Neither the national health services in Europe nor the HMOs in the US.
    29 Jun 2013, 04:19 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|